OXYMETHOLONE (ox-i-meth'oh-lone) Anadrol, Anadrol-50, Anapolon Classifications: hormones and synthetic substitutes; androgen/anabolic steroid Prototype: Testosterone Pregnancy Category: X Controlled Substance: Schedule III
|
50 mg tablets
Potent steroid with anabolic activity. Mechanism of action in refractory anemias is unclear but may be due to direct stimulation
of bone marrow, protein anabolic activity, or to androgenic stimulation of erythropoiesis.
Promotes body tissue building and inhibits tissue-depleting processes; supports nitrogen, potassium, chloride, and phosphorus
conservation. Enhances weight gain and combats depression and weakness in debilitating conditions. Stimulates bone growth,
aids in bone matrix reconstitution, and may support calcification of metastatic lesions of breast cancer.
Aplastic anemia.
Osteoporosis, catabolic conditions.
Prostatic hypertrophy with obstruction; pregnancy (category X); prostatic or male breast cancer; cardiac, renal, hepatic decompensation;
nephrosis; premature infant; use during lactation is not established.
Prepubertal males; geriatric male patients; diabetes mellitus; coronary disease; patient taking ACTH, corticosteroids, anticoagulants.
Aplastic Anemia Adult/Child: PO 15 mg/kg/d
|
Oral
- A course of therapy for treatment of osteoporosis is 721 d.
- For treatment of anemias, a minimum trial period of 36 mo is recommended, since response tends to be slow.
- Store at 15°30° C (59°86° F). Protect from heat and light.
Endocrine: Androgenic in women: Suppression of ovulation, lactation, or menstruation; hoarseness or deepening of voice (often irreversible); hirsutism; oily skin; acne; clitoral enlargement; regression of breasts; male-pattern baldness (in disseminated breast cancer). Hypoestrogenic effects
in women: Flushing, sweating; vaginitis with pruritus, drying, bleeding; menstrual irregularities. Men: prepubertal: premature
epiphyseal closure, phallic enlargement, priapism. Postpubertal: testicular atrophy, decreased ejaculatory volume, azoospermia,
oligospermia (after prolonged administration or excessive dosage), impotence, epididymitis, gynecomastia. CV: Edema, skin flush. GI: Nausea, vomiting, anorexia, diarrhea, jaundice, hepatotoxicity. Urogenital: Bladder irritability. Metabolic: Hypercalcemia.
Drug: May enhance hypoprothrombinemic effects of warfarin. Herbal: Echinacea may increase risk of hepatotoxicity.
Absorption: Readily absorbed from GI tract. Metabolism: Metabolized in liver. Elimination: Excreted in urine. Half-Life: 9 h.
Assessment & Drug Effects
- Monitor patient with a history of seizures closely because an increase in their frequency may be noted.
- Monitor periodically for edema that may develop with or without CHF.
- Monitor for hypercalcemia (see Appendix F), especially in women with breast cancer.
- Lab tests: Periodic serum calcium; periodic liver function tests are especially important for the older adult patient. Drug
should be stopped with first sign of liver toxicity (jaundice).
Patient & Family Education
- Monitor blood glucose for loss of glycemic control if diabetic.
- Women: Notify physician of signs of virilization.
- Do not breast feed while taking this drug without consulting physician.